http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9733575-A1

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b3a790b883cd45182f9cd8618f1c92fb
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_e544a582266040c77f2272e9c9e176f7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2f2c8111feced35067b74fa761712d7a
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-222
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-222
filingDate 1997-03-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_125a48f551e3467c55477ae68463ecca
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5f5111509004a3018e49bfb476cdb0f4
publicationDate 1997-09-18-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber WO-9733575-A1
titleOfInvention Use of tiamulin for preparing a drug for use as a cancer multidrug resistance reversion agent
abstract The use of the antibiotic tiamulin for inducing drug-sensitivity in chemotherapy-resistant human or animal tumour cells as soon as the tumour appears or during tumour development and/or cancer treatment, with a view to preparing a drug for treating malignant blood diseases and solid cancerous tumours in mammals, is disclosed. The cytotoxic activity caused by increased intracellular cancer drug retention may be studied by producing highly resistant tumour lines, i.e. mouse lymphoid leukaemia line P388 resistant to 25 νg/ml of adriamycin, rat hepatocellular carcinoma line AS30-D resistant to 5 and 10 νg/ml of colchicine, and human lymphoblastic leukaemia line CEM resistant to 0.45, 3.6 and 5 νg/ml of vinblastine.
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2017426847-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11576930-B2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2009106839-A1
priorityDate 1996-03-13-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H06128163-A
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/DE-2248237-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-H041132-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226539200
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395766
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID9827044
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID443939
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135743564
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226438198
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135789409
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID30323
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395318
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226447360
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399659
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID56983083
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID4939
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226559707
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID13342
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395470
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID162
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226395471
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID11082
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226559706
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID31703
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6167

Total number of triples: 42.